The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global sleep apnea devices market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Sleep apnea, or sleep-disordered breathing (SDB), is an acute medical condition in which oxygen supply to the brain is obstructed during sleep. It is caused by blockages in the airway resulting in irregular breathing patterns and loud snoring, with the individual often gasping for breath. Sleep apnea diagnostic and therapeutic devices, such as Continuous Positive Airway Pressure (CPAP), Bilevel Positive Airway Pressure (BiPAP) and Variable Positive Airway Pressure (VPAP) machines, are used to evaluate the patient’s respiratory and other bodily functions during sleep. Apart from this, numerous oral devices, including the Mandibular Advancement Device (MAD) and tongue retaining device, are also utilized to treat mild to moderate cases of sleep apnea.
The increasing prevalence of obstructive sleep apnea disorder (OSA), central sleep apnea and complex sleep apnea syndrome, are among the key factors driving the growth of the market. Such disorders are highly prevalent among the geriatric population and individuals suffering from other ailments, such as diabetes, hypertension and cardiovascular diseases (CVDs), which is facilitating product adoption across both the developed and emerging nations. Furthermore, product innovations, including Out-of-Center (OOC) testing devices that examine sleep patterns, cardiovascular, oximetry and respiratory parameters for the diagnosis of OSA is also acting as another major growth-inducing factor. Other factors, including improving healthcare infrastructure and growing awareness regarding the prolonged effects of sleep apnea, along with the miniaturization and launch of affordable devices by various brands, are projected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global sleep apnea devices market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product type and end-user.
Breakup by Product Type:
Breakup by End-User:
Brealup by Region:
The competitive landscape of the industry has also been examined with some of the key players being BMC Medical Co., Braebon Medical Corporation, Cadwell Laboratories, CareFusion Corp., Curative Medical, Devilbiss Healthcare, Fisher & Paykel Healthcare, GE Healthcare, Invacare, Oventus Medical, Panthera Dental, ResMed, Somnomed Ltd., Vyaire Medical Inc., Whole You Inc., etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product Type, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico, Argentina, Colombia, Chile, Peru, Turkey, Saudi Arabia, Iran, United Arab Emirates|
|Companies Covered||BMC Medical Co., Braebon Medical Corporation, Cadwell Laboratories, CareFusion Corp., Curative Medical, Devilbiss Healthcare, Fisher & Paykel Healthcare, GE Healthcare, Invacare, Oventus Medical, Panthera Dental, ResMed, Somnomed Ltd., Vyaire Medical Inc. and Whole You Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at